We use cookies on this site to enable your digital experience. By continuing to use this site, you are agreeing to our cookie policy. close

Feature

Actavis At 5: Where Pay-For-Delay Litigation Stands

Law360 (August 6, 2018, 6:47 PM EDT) -- It’s been a little over five years since the U.S. Supreme Court issued its landmark Actavis decision that found payments made by brand-name drugmakers to generics makers in patent settlements can raise antitrust concerns. But uncertainty over which pay-for-delay deals actually are illegal continues and recent lower court rulings have cut both ways, with some cases fizzling out and others forging ahead.

Here, Law360 looks at some of those recent rulings and where pay-for-delay litigation currently stands.

First Circuit

Case: In re: Loestrin 24 Fe Antitrust...
To view the full article, register now.